AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23958371 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral letters from primary care to specialised mental health care
Number of subjects: 4
Study 23958371 — intervention group
Group type: COMPARATOR
Intervention: General guidelines and guidelines for somatic care
Number of subjects: 4
Study 23958434 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported BMI (29.0±8.37 kg/m(2))
Number of subjects: 60
Study 23958434 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported height
Number of subjects: 60
Study 23958434 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weight
Number of subjects: 60
Study 23958434 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported BMI
Number of subjects: 60
Study 23958434 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported BMI category
Number of subjects: 60
Study 23958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD)
Number of subjects: 0
Study 23959571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT)
Number of subjects: 3057
Study 23959571 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 3057
Study 23959743 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric annuloplasty ring and leaflet reconstruction with concomitant sinus and ascending aortic graft replacement
Number of subjects: 6
Study 23959756 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed early mobilisation intervention in the surgical ICU
Number of subjects: 200
Study 23959883 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere interaction
Number of subjects: 0
Study 23959883 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere interaction
Number of subjects: 0
Study 23959883 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of lateralization
Number of subjects: 0
Study 23961354 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient assistance program information
Number of subjects: 333
Study 23961354 — intervention group
Group type: COMPARATOR
Intervention: Department of Health pamphlet about breast cancer and treatment
Number of subjects: 333
Study 23962071 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine
Number of subjects: 610
Study 23963055 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of transdermal nicotine (mean NRT dose 32.7 mg/d; range, 7-56 mg/d)
Number of subjects: 12
Study 23963055 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of transdermal nicotine
Number of subjects: 12
Study 23965261 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational pharmacotherapy
Number of subjects: 50
Study 23965279 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia intervention with personalized health messages and health goal selection
Number of subjects: 367
Study 23965279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 367
Study 23965279 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia intervention
Number of subjects: 367
Study 23965279 — intervention group
Group type: EXPERIMENTAL
Intervention: MI and GRS reports
Number of subjects: 367
Study 23965300 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized exercise intervention
Number of subjects: 39
Study 23965778 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive men
Number of subjects: 1813
Study 23965778 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative men
Number of subjects: 1813
Study 23965778 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HPV prevalence
Number of subjects: 1813
Study 23965778 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV types 16 and 18 among HIV-positive men
Number of subjects: 1813
Study 23965778 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV types 52, 51, 16, 18, 35, and 66
Number of subjects: 1813
Study 23965936 — intervention group
Group type: EXPERIMENTAL
Intervention: e-counselling
Number of subjects: 528
Study 23965936 — intervention group
Group type: COMPARATOR
Intervention: Control (general educational e-messages)
Number of subjects: 528
Study 23966244 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 to 16 weeks
Number of subjects: 105
Study 23966428 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g Ca + 400 IU vitamin D3/d (Calcium/Vitamin D Trial)
Number of subjects: 128779
Study 23966428 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vitamin D intake ≥400 IU/d
Number of subjects: 128779
Study 23966579 — intervention group
Group type: COMPARATOR
Intervention: TK1 activity in BRCA1/2 mutation carriers
Number of subjects: 80
Study 23966579 — intervention group
Group type: COMPARATOR
Intervention: sEGFR concentration in BRCA1 mutation carriers
Number of subjects: 80
Study 23966579 — intervention group
Group type: EXPERIMENTAL
Intervention: TK1 activity in women who developed breast cancer
Number of subjects: 80
Study 23966579 — intervention group
Group type: EXPERIMENTAL
Intervention: sEGFR concentration in women who developed breast cancer
Number of subjects: 80
Study 23966579 — intervention group
Group type: COMPARATOR
Intervention: sEGFR concentration in women with BSO
Number of subjects: 80
Study 23966867 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) for waist circumference (WC) adjusted for BMI
Number of subjects: 33591
Study 23966867 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) for waist-hip ratio (WHR) adjusted for BMI
Number of subjects: 33591
Study 23966867 — intervention group
Group type: COMPARATOR
Intervention: Previously reported loci for waist in European ancestry (EA) populations
Number of subjects: 33591
Study 23966867 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with metabolic traits
Number of subjects: 33591
Study 23966867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual dimorphism analysis
Number of subjects: 33591
Study 23967125 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours aerobic exercise (50% of VO2max)
Number of subjects: 18
Study 23968316 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
Number of subjects: 333
Study 23968316 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient training programme
Number of subjects: 333
Study 23968744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk-based preterm formula (BOV)
Number of subjects: 0
Study 23968744 — intervention group
Group type: COMPARATOR
Intervention: Exclusive human milk diet of pasteurized donor human milk and human milk-based human milk fortifier (HUM)
Number of subjects: 0
Study 23969187 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.22 mg/kg/d) for 12 months
Number of subjects: 5
Study 23969187 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin treatment for 12 months
Number of subjects: 5
Study 23969281 — intervention group
Group type: EXPERIMENTAL
Intervention: Actions taken to relieve withdrawal symptoms (e.g., nicotine use)
Number of subjects: 120
Study 23969281 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms (e.g., anxiety, cannabis craving)
Number of subjects: 120
Study 23969281 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting strategies used to maintain abstinence
Number of subjects: 120
Study 23969281 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identified most helpful quitting strategy
Number of subjects: 120
Study 23969476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradycardia pacemaker (PM) implantation
Number of subjects: 1517
Study 23969476 — intervention group
Group type: COMPARATOR
Intervention: Bradycardia pacemaker (PM) implantation without concomitant cardiovascular disease
Number of subjects: 1517
Study 23969788 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical cytoreduction to microscopic residual
Number of subjects: 189
Study 23969788 — intervention group
Group type: COMPARATOR
Intervention: Residual disease status
Number of subjects: 189
Study 23969788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade serous carcinoma with measurable residual disease
Number of subjects: 189
Study 23970149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 158
Study 23970502 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010 McDonald criteria for MS diagnosis
Number of subjects: 109
Study 23970502 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of symptomatic lesions in DIT criteria
Number of subjects: 109
Study 23970502 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010 DIS criteria
Number of subjects: 109
Study 23970502 — intervention group
Group type: COMPARATOR
Intervention: 2005 DIS criteria
Number of subjects: 109
Study 23970541 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise (1 hour, three times per week for 16 weeks)
Number of subjects: 38
Study 23970541 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Number of subjects: 38
Study 23970541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supervised physical exercise)
Number of subjects: 38
Study 23970541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 23970725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone treatment
Number of subjects: 0
Study 23971740 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.75 mcg/day
Number of subjects: 40
Study 23971740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23971740 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol + Lisinopril
Number of subjects: 40
Study 23971740 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Lisinopril
Number of subjects: 40
Study 23972303 — intervention group
Group type: EXPERIMENTAL
Intervention: Average RNFL thickness < 86 μm
Number of subjects: 287
Study 23972303 — intervention group
Group type: EXPERIMENTAL
Intervention: Average RNFL thickness > 86 μm
Number of subjects: 287
Study 23972346 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED infection
Number of subjects: 64893
Study 23972346 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED infection in women
Number of subjects: 64893
Study 23972346 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED infection in women compared to men
Number of subjects: 64893
Study 23972346 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED infection after index admission
Number of subjects: 64893
Study 23972788 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 0
Study 23973693 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest HDL-C quartile
Number of subjects: 2193
Study 23973693 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest HDL-C quintile among subjects with LDL-C <70 mg/dl
Number of subjects: 2193
Study 23973693 — intervention group
Group type: COMPARATOR
Intervention: Lowest HDL-C quartile
Number of subjects: 2193
Study 23974909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography (CT)
Number of subjects: 18
Study 23974925 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake and fed thermogenesis (AFT)
Number of subjects: 509
Study 23974925 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 509
Study 23974925 — intervention group
Group type: EXPERIMENTAL
Intervention: AFT normalized as a percentage of intake
Number of subjects: 509
Study 23974925 — intervention group
Group type: EXPERIMENTAL
Intervention: AFT
Number of subjects: 509
Study 23974925 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual variance of AFT
Number of subjects: 509
Study 23974944 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking intervention (3 times/week for 3 months)
Number of subjects: 44
Study 23975330 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity assessed by accelerometer (counts/minute)
Number of subjects: 1345
Study 23975330 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity assessed by 7-day PAR (MET/hour/week)
Number of subjects: 1345
Study 23975330 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (counts/minute)
Number of subjects: 1345
Study 23975330 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (MET/hour/week)
Number of subjects: 1345
Study 23975330 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity measures
Number of subjects: 1345
Study 23975665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² at week 1, then 250 mg/m²/week) and Gemcitabine (1 g/m² on day 1, 8 and 15 every 4 weeks)
Number of subjects: 44
Study 23975665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and Gemcitabine
Number of subjects: 44
Study 23976960 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent surface antigen, inactivated influenza vaccine (15 µg hemagglutinin of each virus strain)
Number of subjects: 126
Study 23976960 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent surface antigen, inactivated influenza vaccine
Number of subjects: 126
Study 23977071 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) implantation in a non-hospital setting
Number of subjects: 65
Study 23977071 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) implantation
Number of subjects: 65
Study 23978163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBMNC transplantation and rehabilitation therapy
Number of subjects: 37
Study 23978163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBMNC and UCMSC transplantation and rehabilitation therapy
Number of subjects: 37
Study 23978163 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation therapy only)
Number of subjects: 37
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: 24 h-CASP (114 ± 17 mmHg in C, 115 ± 13 in SN, 121 ± 13 in LN, 119 ± 16 in Mi, 121 ± 13 in Ma)
Number of subjects: 715
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: 24 h-CPP (38 ± 8 mmHg in C, 38 ± 7 in SN, 44 ± 10 in LN, 46 ± 11 in Mi, 46 ± 11 in Ma)
Number of subjects: 715
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: Odds ratios for CVD per 1 standard deviation increase in 24 h-CASP
Number of subjects: 715
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: Odds ratios for CVD per 1 standard deviation increase in 24 h-CPP
Number of subjects: 715
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: Odds ratios for retinopathy per 1 standard deviation increase in 24 h-CASP
Number of subjects: 715
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: Odds ratios for retinopathy per 1 standard deviation increase in 24 h-CPP
Number of subjects: 715
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: Odds ratios for autonomic dysfunction per 1 standard deviation increase in 24 h-CASP
Number of subjects: 715
Study 23978271 — intervention group
Group type: COMPARATOR
Intervention: Odds ratios for autonomic dysfunction per 1 standard deviation increase in 24 h-CPP
Number of subjects: 715
Study 23978364 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 1434
Study 23978364 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1434
Study 23978364 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer agents (prasugrel or ticagrelor)
Number of subjects: 1434
Study 23978572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovation Abdominal Stent Graft System
Number of subjects: 161
Study 23978690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone with diabetes diary application and health counseling
Number of subjects: 151
Study 23978690 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone with diabetes diary application without health counseling
Number of subjects: 151
Study 23979273 — intervention group
Group type: EXPERIMENTAL
Intervention: mtDNA DAMP levels in patients with SIRS
Number of subjects: 4
Study 23979273 — intervention group
Group type: EXPERIMENTAL
Intervention: mtDNA DAMP levels in patients who developed MODS
Number of subjects: 4
Study 23979273 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median mtDNA DAMP levels
Number of subjects: 4
Study 23979273 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died secondary to severe MODS
Number of subjects: 4
Study 23979288 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 40
Study 23979288 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification and medical therapy
Number of subjects: 40
Study 23979353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy for 12 months
Number of subjects: 746
Study 23979626 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD System (Cameron Health/Boston Scientific)
Number of subjects: 330
Study 23979733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus Dolutegravir (DTG) 50 mg every 24 h for 5 days
Number of subjects: 27
Study 23979733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus GSK1265744 30 mg every 24 h for 12 days
Number of subjects: 27
Study 23979733 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir (DTG) 50 mg every 24 h for 5 days
Number of subjects: 27
Study 23979733 — intervention group
Group type: COMPARATOR
Intervention: GSK1265744 (30 mg every 24 h for 12 days)
Number of subjects: 27
Study 23979787 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet plan for 2 months
Number of subjects: 29
Study 23980534 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 13
Study 23980906 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine HCl (1500 mg orally with 90 mL of water)
Number of subjects: 6
Study 23981504 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical microemulsion
Number of subjects: 0
Study 23981504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23981683 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologists' assessment of medical history, physical examination, and laboratory tests.
Number of subjects: 949
Study 23981683 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologists' assessment with added diagnostic laboratory tests.
Number of subjects: 949
Study 23981683 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients diagnosed with PsA.
Number of subjects: 949
Study 23982845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg)
Number of subjects: 34
Study 23982845 — intervention group
Group type: COMPARATOR
Intervention: Control (no ocriplasmin injection)
Number of subjects: 34
Study 23982860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 6 (BMP-6) overexpression via adeno-associated virus-mediated gene transfer in C57BL/6 mice
Number of subjects: 0
Study 23982860 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study 23982888 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 12866
Study 23982888 — intervention group
Group type: EXPERIMENTAL
Intervention: Each standard deviation decline in estimated GFR
Number of subjects: 12866
Study 23982888 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria and hematuria (markers of kidney damage)
Number of subjects: 12866
Study 23982906 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 177
Study 23982906 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 177
Study 23983212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 600 mg twice daily for up to 10 days
Number of subjects: 130
Study 23983245 — intervention group
Group type: EXPERIMENTAL
Intervention: Multielectrode radiofrequency (MER) system with procedural changes (therapeutic vitamin K antagonist and heparin, submerged loading of the catheter, deactivation of either distal or proximal electrode)
Number of subjects: 60
Study 23983245 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 23983680 — intervention group
Group type: EXPERIMENTAL
Intervention: HP eradication
Number of subjects: 0
Study 23983680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive HP strains
Number of subjects: 0
Study 23983680 — intervention group
Group type: EXPERIMENTAL
Intervention: OLGA staging system and tissue biomarkers integration
Number of subjects: 0
Study 23983680 — intervention group
Group type: EXPERIMENTAL
Intervention: RPRM as circulating cell-free DNA
Number of subjects: 0
Study 23983684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 μg/kg dexmedetomidine
Number of subjects: 60
Study 23983684 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study 23983690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D software planning, guided surgery, immediate loading, CAD-CAM full arch frameworks
Number of subjects: 20
Study 23983804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense multipurpose exercise program (EG)
Number of subjects: 137
Study 23983807 — intervention group
Group type: EXPERIMENTAL
Intervention: TZD + EA (Electroacupuncture)
Number of subjects: 31
Study 23983807 — intervention group
Group type: COMPARATOR
Intervention: TZD (Control)
Number of subjects: 31
Study 23983807 — intervention group
Group type: EXPERIMENTAL
Intervention: TZD + EA
Number of subjects: 31
Study 23983807 — intervention group
Group type: COMPARATOR
Intervention: TZD
Number of subjects: 31
Study 23983823 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus STn-KLH vaccine
Number of subjects: 1028
Study 23983823 — intervention group
Group type: COMPARATOR
Intervention: KLH alone
Number of subjects: 1028
Study 23983823 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus STn-KLH vaccine with median or greater antibody response
Number of subjects: 1028
Study 23983980 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 178
Study 23983980 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine IR
Number of subjects: 178
Study 23984046 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine + phenylalanine (1 mmol/kg fat free body mass each) + 25 g glucose
Number of subjects: 8